Literature DB >> 2245336

Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease.

D J Skene1, B Vivien-Roels, D L Sparks, J C Hunsaker, P Pévet, D Ravid, D F Swaab.   

Abstract

Melatonin and 5-methoxytryptophol (ML) were measured in human pineals (38 controls, 16 subjects with Alzheimer's disease). Time of death had a major influence on the indole concentrations with significantly higher melatonin levels occurring at night (22.00-10.00 h) and significantly higher ML levels occurring during the day (10.00-22.00 h). This daily variation disappeared in both the older subjects (55-92 years) and in the Alzheimer patients (55-89 years).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245336     DOI: 10.1016/0006-8993(90)90214-v

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  36 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

3.  Antioxidants and Neuron-Astrocyte Interplay in Brain Physiology: Melatonin, a Neighbor to Rely on.

Authors:  Antonio Gonzalez
Journal:  Neurochem Res       Date:  2020-01-27       Impact factor: 3.996

4.  Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide.

Authors:  M A Pappolla; M Sos; R A Omar; R J Bick; D L Hickson-Bick; R J Reiter; S Efthimiopoulos; N K Robakis
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

Review 5.  Treatment of Sleep Disorders in Dementia.

Authors:  Sharon Ooms; Yo-El Ju
Journal:  Curr Treat Options Neurol       Date:  2016-09       Impact factor: 3.598

Review 6.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

7.  Learning to live on a Mars day: fatigue countermeasures during the Phoenix Mars Lander mission.

Authors:  Laura K Barger; Jason P Sullivan; Andrea S Vincent; Edna R Fiedler; Laurence M McKenna; Erin E Flynn-Evans; Kirby Gilliland; Walter E Sipes; Peter H Smith; George C Brainard; Steven W Lockley
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

Review 8.  Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.

Authors:  N Zisapel
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

9.  Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease.

Authors:  S Duleu; A Mangas; F Sevin; B Veyret; A Bessede; M Geffard
Journal:  Int J Alzheimers Dis       Date:  2010-03-15

Review 10.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.